Recent diabetes guidelines have suggested giving type 2 diabetes patients newer glucose-lowering drugs like SGLT2 inhibitors, GLP-1 agonists, and DPP-4 inhibitors, earlier in preference to older drugs like metformin and the sulfonylureas, due to their many benefits. However, for Medicare recipients, the out-of-pocket costs for these drugs are much higher. Read more